Laryngeal cancer outcomes vary wildly by tumor type, study reveals
A new analysis shows survival rates for laryngeal cancer range from 95% to 17% depending on histologic subtype—a critical distinction currently lost in clinical data that pools all cases together. The findings suggest oncologists and health systems need better diagnostic protocols and tailored treatment strategies to improve patient outcomes and resource allocation.
Originaltitel: "Histologic type, treatment and prognosis of carcinomas of the larynx: A review".
Halva delen av larynxcancerfall klassificeras felaktigt när patologer aggregerar alla histologiska typer tillsammans — en praxis som maskerar kritiska prognostiska skillnader och hindrar målriktad behandling. Översynen från Hospital Universitario Central de Asturias och Sahlgrenska Academy visar att överlevnaden varierar från cirka 95 procent i verrucös skivepitelcancer till 17 procent i småcellig neuroendokrin cancer. Salivärtyper följer oftast långsamma naturliga förlopp, medan NUT-carcinomer är snabbtProgressiv och begränsar möjligheten till organbevarande behandling. Författarna argumenterar att histologtypen tillsammans med tumörstadium och komorbiditeter är en huvudsaklig faktor för val av terapi och prognos. För inköpschefer och chefsläkare betyder detta att diagnostisk precision — genom raffinerad klassificering av sällsynta entiteter — blir central för att justera behandlingsvägen och förbättra patientutfall inom larynxoncologi.
Carcinomas of the larynx encompass a heterogeneous group of tumors with markedly different biological behaviors. Conventional squamous cell carcinoma (SCC) accounts for most cases; however, less common non-SCC histologies, including salivary-type tumors, neuroendocrine carcinomas (NEC), and NUT carcinoma, exhibit distinct biological behaviors and survival outcomes. Despite these differences, most clinical reports and epidemiological datasets aggregate all laryngeal cancers together, which limit prognostic discrimination and may hinder treatment optimization. This narrative review summarizes current evidence regarding the impact of the histologic type on treatment strategies and prognosis in laryngeal carcinomas, highlighting the clinical implications of tumor biology. The survival varies substantially across histologic subtypes, ranging from approximately 95% in verrucous squamous cell carcinoma to 17% in small-cell NEC considering all stages. Salivary-type tumors often follow indolent natural histories. In contrast, NUT carcinoma is associated with rapidly progressive disease and limited organ preservation potential. These variations reflect a spectrum of biological and clinical differences that translate into divergent therapeutic paradigms. The histologic type together with stage and associated comorbidities is a major determinant of treatment modality selection and prognosis in laryngeal carcinomas. Emphasizing histology-based decision-making and refining classification of rare entities may improve the therapeutic precision and clinical outcomes.